WCBA
ALXN

Weaver C. Barksdale & Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-15,500
Closed -$2.69M – 569
2015
Q1 		$2.69M Hold
15,500
– – 2.02% 14
2014
Q4 		$2.87M Hold
15,500
– – 2.31% 4
2014
Q3 		$2.57M Buy
15,500
+2,400
+18% +$394K 2.12% 5
2014
Q2 		$2.05M Buy
+13,100
New +$2.07M 1.65% 29

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Weaver C. Barksdale & Associates's ALXN Position: Q2 2015 in Review

Weaver C. Barksdale & Associates sold out of Alexion Pharmaceuticals (ALXN) in Q2 2015, closing a stake of 15,500 shares — an estimated $2.69M sold.

Weaver C. Barksdale & Associates first reported a position in ALXN in Q2 2014 and held it in 4 quarters. The position peaked at $2.87M in Q4 2014. 548 funds tracked by Wall St. Rank hold ALXN as of Q2 2015.

  • Weaver C. Barksdale & Associates reported no remaining Alexion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Weaver C. Barksdale & Associates sold 15,500 Alexion Pharmaceuticals shares in Q2 2015, an estimated $2.69M.
  • Weaver C. Barksdale & Associates first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 4 quarters.
  • Weaver C. Barksdale & Associates's Alexion Pharmaceuticals position peaked at $2.87M in Q4 2014.
  • 548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2015.

Based on Weaver C. Barksdale & Associates's 13F filing for Q2 2015, filed 17 Jul 2015.